Table 1.
Association of programmed cell death protein 1 (PD1) expression by tumor infiltrating lymphocytes (TILs) with clinicopathologic parameters in 182 patients with esophageal adenocarcinoma
| Factor | Adenocarcinoma (n = 168) n (%) | PD1+ TILs (n = 136) n (%) | PD1− TILs (n = 32) n (%) | p value |
|---|---|---|---|---|
| Tumor stage | ||||
| High-grade dysplasia | 4 (2.4) | 1 (25) | 3 (75) | <0.001 |
| pT1a | 13 (7.7) | 5 (38.5) | 8 (61.5) | |
| pT1b | 20 (11.9) | 7 (35) | 13 (65) | |
| pT2 | 49 (29.2) | 45 (91.8) | 4 (8.2) | |
| pT3 | 77 (45.8) | 76 (98.7) | 1 (1.3) | |
| pT4 | 5 (3) | 2 (40) | 3 (60) | |
| Lymph node status | ||||
| pNx | 13 (7.7) | 0.007 | ||
| pN0 | 61 (36.3) | 41 (67.2) | 20 (32.8) | |
| pN1 | 31 (18.5) | 28 (90.3) | 3 (9.7) | |
| pN2 | 26 (15.5) | 24 (92.3) | 2 (7.7) | |
| pN3 | 37 (22) | 32 (86.5) | 5 (13.5) | |
| Histologic grading | ||||
| G1 | 7 (4.2) | 5 (71.4) | 2 (28.6) | 0.350 |
| G2 | 74 (44) | 57 (77) | 17 (23) | |
| G3 | 87 (51.8) | 74 (85.1) | 13 (14.9) | |
| Neoadjuvant therapy | ||||
| Yes | 63 (37.5) | 54 (85.7) | 9 (14.3) | 0.223 |
| Total resection | ||||
| Yes | 145 (86.3) | 115 (79.3) | 30 (20.7) | 0.174 |
| No | 23 (13.7) | 21 (91.3) | 2 (8.7) | |
| Siewert classification | ||||
| AEG 1 | 101 (60.1) | 76 (75.2) | 25 (24.8) | 0.016 |
| AEG 2 | 44 (26.2) | 42 (95.5) | 2 (4.5) | |
| AEG 3 | 23 (13.7) | 18 (78.3) | 5 (21.7) | |
| PD1 expression by TILs | ||||
| 0 (0%) | 32 (19) | |||
| 1+ (5–25%) | 56 (33.3) | |||
| 2+ (26–50%) | 68 (40.5) | |||
| 3+ (51–75%) | 12 (7.1) | |||
| 4+ (76–100%) | 0 | |||
AEG adenocarcinoma of the esophagogastric junction